Meng Law

Professor and Director of Radiology

MONASH UNIVERSITY
Country flagAustralia
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Objectives: The severe cerebral atrophy patterns of progressive supranuclear palsy (PSP) create challenges in clinical neuroradiology practice and neuroimaging research as often, subcortical regions are not accurately segmented with existing atlases or require labour intense manual segmentation. We aimed to create a PSP specific neuroimaging atlas. Methods: Seven subcortical regions were manually segmented on Quantitative Susceptibility Mapping (QSM) images of 34 PSP Richardson’s Syndrome (PSP-RS) subjects and used to automatically segment five validation subjects using the ANTs Joint Label Fusion module. Accuracy was confirmed by manual segmentation of QSM images of the validation subjects as the gold standard. Results: The PSP atlas outperformed existing atlases with median dice coefficient and 95% Hausdorff Distance of 0.88 (0.84-0.90) and 1.13mm (1.13-1.60) compared to 0.69 (0.65-0.76) and 3.3mm (2.53-5.12) for Talaraich and Harvard-Oxford atlases. Conclusions: Our new PSP subcortical atlas outperforms currently available atlases and can be applied to multimodal datasets and T1-weighted images alone.

Year:

2026

Biomarkers from diverse methodological domains are increasingly important in the detection, diagnosis and tracking of neurological diseases and brain health, yet they are often evaluated in isolation. Statistical integration approaches, such as factor analysis, provide a means to combine complementary biomarkers and capture higher-order domains of brain health. Exploratory factor analysis has previously been employed to identify latent brain health constructs using multimodal MRI, fluid biomarkers and cardiovascular risk factors in a non-clinical older population. The current study aimed to validate this integrative framework using confirmatory factor analysis in an independent cohort and test construct associations with cognition and diagnosis of mild cognitive impairment (MCI) or Alzheimer’s disease (AD) dementia. Data were analysed from 197 participants in the Prospective Imaging Study of Ageing, including 157 cognitively normal controls (CN), 18 participants with MCI and 22 participants with early AD dementia. MRI, cardiovascular, and plasma biomarker processing closely replicated previous methods. Confirmatory factor analysis was conducted in CNs to validate the previously reported latent constructs. Weighted factor composites were then compared between each diagnostic group and tested for associations with cognitive performance (verbal reasoning, verbal memory, visual memory and language) and sensitivity to MCI and AD diagnosis. Three factors were reproducible across cohorts: 1) Brain & Vascular Health (hippocampal and ventricular volumes, cerebral blood flow); 2) White Matter (WM) Fluid Dysregulation (Free Water, WM enlarged perivascular spaces); and 3) Blood Biomarkers (GFAP, NfL, pTau181). Compared to the CN group, both MCI (β=−1.25, SE=0.19, p <.001) and AD dementia (β=−1.52, SE=0.16, p <.001) participants had lower Brain & Vascular Health composite scores. MCI (β=0.80, SE=0.20, p <.001) and AD dementia (β=1.85, SE=0.17, p <.001) participants also had higher Blood Biomarkers composite scores than CNs, but there was no difference in WM Fluid Dysregulation scores across groups (F (2,192) = 0.89, p =.411). The Brain & Vascular Health composite had the strongest association with MCI/AD dementia among all individual measures and composites. Across all participants, Brain & Vascular Health and Blood Biomarkers composite scores were associated with tests of cognition ( p <.0125), while WM Fluid Dysregulation did not show any significant associations. These findings demonstrate that reproducible, multimodal composites can index distinct yet complementary dimensions of brain health relevant to cognition and AD dementia. Importantly, this work highlights the value of an adaptable, integrative framework for combining imaging and plasma biomarkers to characterise system-level brain health and support early detection and mechanistic investigation of cognitive decline and neurodegenerative disease.

Year:

2026

Individual imaging and fluid biomarkers provide insights into specific components of brain health, but integrated multimodal approaches are necessary to capture the complex, interrelated biological systems that contribute to brain homeostasis and neurodegenerative disease. Using data from the Brain and Cognitive Health (BACH) cohort study (N=127; mean age=67 years, 68% women), we performed an exploratory factor analysis to identify latent constructs of brain health. We included multimodal neurovascular imaging markers, brain atrophy metrics, plasma Alzheimer’s disease (AD) biomarkers and cardiovascular risk factors. Five constructs emerged: “Brain & Vascular Health” (greater hippocampal volume, basal ganglia enlarged perivascular spaces [ePVS], cerebral blood flow and HDL cholesterol; lower ventricle volume and BMI); “Structural Integrity” (greater cortical thickness, fractional anisotropy and basal ganglia ePVS); “Fluid Transport” (greater white matter ePVS and Free Water); “AD Biomarkers” (higher phosphorylated tau [pTau]181 and pTau217; lower amyloid-beta 42/40 ratio); and “Neuronal Injury” (higher glial fibrillary acidic protein and neurofilament light chain). All constructs were associated with age (β=-0.70–0.39, p ≤.014), except for Fluid Transport ( p >.05). Brain & Vascular Health and Structural Integrity ( partial r =.305, p <.001), and AD Biomarkers and Neuronal Injury ( partial r =.248, p =.005) were positively correlated. Only Brain & Vascular Health was associated with global cognition (β=0.27, SE=0.13, p =.043). These findings provide a data-driven framework for examining distinct constructs underlying vascular health, fluid regulation and neurodegenerative pathology. We demonstrate the utility of using multiple biomarkers to probe these biological systems, paving the way for future research to explore how these systems change across diverse neurodegenerative conditions.

Year:

2025

Plasma biomarkers are promising for detecting Alzheimer’s disease (AD) pathology, but their role in cognitively healthy individuals remains unclear. Plasma pTau-217 has high diagnostic accuracy for clinical and prodromal AD, yet its relevance in preclinical stages is underexplored. We examined if plasma biomarkers of AD, neurodegeneration, and neuroinflammation were associated with cognition, brain structure, and their cerebrospinal fluid (CSF) counterparts in dementia-free older adults. We studied community-based, dementia-free older adults from the Brain and Cognitive Health (BACH) cohort. Neuropsychological testing assessed global cognition (MMSE), memory (Logical Memory II), visual processing (Hooper Visual Organization Test), processing speed (Trail Making Test-A), and reasoning (Similarities). Paired plasma and CSF biomarkers (pTau-217, pTau-181, GFAP, NfL, Aβ42/40) were measured using SIMOA. MRI-derived cortical thickness was used as a neurodegeneration marker. Multivariable linear regression assessed associations between log 10 -transformed plasma biomarker levels, cognition (adjusted for age, sex, education, hypertension, hyperlipidemia, diabetes), and cortical thickness (adjusted for age, sex, education, and intracranial volume). Pearson’s correlations and Bland-Altman plots evaluated plasma-CSF agreement. There were 147 dementia-free participants (mean age±SD: 66.7±7.7 years; 56 % women). Higher plasma pTau-217 levels associated with lower global cognition scores (β -0.80, 95% C.I. -1.56, -0.03, p=0.041) and abstract reasoning (β -0.86, 95% confidence interval [C.I.] -1.62, -0.09, p=0.028). Greater plasma pTau-217 also associated with lower global cortical thickness (βeta [β] -0.21, 95% confidence interval [C.I]. -0.37, -0.06, per log unit change; p=0.006). No associations were found between the plasma biomarkers and processing speed or visual processing (p>0.05 for all). Among 47 participants with paired plasma-CSF biomarkers, plasma pTau-217 showed the strongest correlation with its CSF counterpart (R=0.76, p<0.0001), outperforming pTau-181 (R=0.61, p<0.0001), GFAP (R=0.66, p<0.0001), NfL (R=0.56, p<0.0001), and Aβ42/40 (R=0.53, p=0.0001). In conclusion, plasma pTau-217 levels were associated with both cognition and cortical thickness in dementia-free older adults. All plasma biomarkers correlated significantly with their CSF counterpart. These findings reinforce the utility of plasma biomarkers, particularly pTau-217, as indicators of neurodegenerative processes, even in asymptomatic individuals.

Year:

2025

Collaborators (16)

Jurgen Fripp

Biomedical Informatics Group Leader

CSIRO

AUSTRALIA
View details

Nicholas Ashton

Assistant Professor

Banner Alzheimer’s Institute

UNITED STATES
View details

Trevor Chong

MONASH UNIVERSITY

AUSTRALIA
View details

Henrik Zetterberg

Professor

University of Gothenburg

SWEDEN
View details

Stephanie Yiallourou

Senior Research Fellow

MONASH UNIVERSITY

AUSTRALIA
View details

Ian H. Harding

Group Leader

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Terence O'Brien

MONASH UNIVERSITY

AUSTRALIA
View details

Matthew Pase

Associate Professor

MONASH UNIVERSITY

AUSTRALIA
View details

Danny Wang

Professor

University of Southern California

UNITED STATES
View details

Lucy Vivash

MONASH UNIVERSITY

AUSTRALIA
View details

Marina Cavuoto

Senior Research Fellow

National Ageing Research Institute

AUSTRALIA
View details

Michelle Lupton

Team Head

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Mujun Sun

MONASH UNIVERSITY

AUSTRALIA
View details

Stuart McDonald

Senior Research Fellow

MONASH UNIVERSITY

AUSTRALIA
View details

Michael Breakspear

Professor

Newcastle University

AUSTRALIA
View details

Gail A. Robinson

University of Queensland

AUSTRALIA
View details